rheumatoid arthritis news from FiercePharma
News
ALSO NOTED: Forest takes charge on Azor split; GSK launches Tykerb-Herceptin trials;
> Forest Laboratories will take a $44.1 million charge on termination of its deal to co-promote the hypertension drug Azor with Daiichi Sankyo. Read more...
Enbrel gets black-box infection warning
Enbrel's new black box is now official. Wyeth and Amgen have put the final touches on a Read more...
SPOTLIGHT: Rituxan falls short in lupus trial
In a big disappointment for Genentech and Biogen Idec, Rituxan failed its late-stage test against lupus. Already approved for non-Hodgkins lymphoma and rheumatoid arthritis treatment, Rituxan might Read more...
As former exec indicted, BMS posts growth
A triad of Bristol-Myers Squibb news today, some good, some not-so-good. First, let's get the earnings out of the way: The company reported a decline in earnings on restructuring charges, but Read more...
ALSO NOTED: GSK to invest $47M in Irish plant; AstraZeneca, GSK get downgraded;
> GlaxoSmithKline is set to create 50 new jobs in Dungarvan, Ireland, over the next three years with a $47 million expansion of its over-the-counter manufacturing facility there. Read more...
ALSO NOTED: J&J reports big revenue growth; Drugmakers fight U.K.'s Aricept ruling;
> Johnson & Johnson reported a 7.7 percent increase in first-quarter sales, to a record-setting $16.2 billion; EPS grew by 8.6 percent to $1.26 excluding special charges. Read more...
SPOTLIGHT: Insurers hike co-pays for expensive meds
Health insurers are passing on the high cost of some meds to patients, asking them to pay up to one-third the price of expensive drugs; the policies affect drugs for such serious illnesses as Read more...
BMS, Repligen settle Orencia fight
Four companies, two disputed patents, two multimillion-dollar settlements. Repligen and Bristol-Myers Squibb buried the hatchet over Orencia, the rheumatoid arthritis treatment that's been subject Read more...
Get more rheumatoid arthritis coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight